Immune Netw.  2016 Apr;16(2):99-108. 10.4110/in.2016.16.2.99.

Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells

• Kim JS
• Kim YG
• Park EJ
• Kim B
• Lee HK
• Hong JT
• Kim Y
• Han SB

• KMID: 2168050
• DOI: http://doi.org/10.4110/in.2016.16.2.99

Abstract

Colorectal cancer is the third leading cancer worldwide. Although incidence and mortality of colorectal cancer are gradually decreasing in the US, patients with metastatic colorectal cancer have poor prognosis with an estimated 5-year survival rate of less than 10%. Over the past decade, advances in combination chemotherapy regimens for colorectal cancer have led to significant improvement in progression-free and overall survival. However, patients with metastatic disease gain little clinical benefit from conventional therapy, which is associated with grade 3~4 toxicity with negative effects on quality of life. In previous clinical studies, cell-based immunotherapy using dendritic cell vaccines and sentinel lymph node T cell therapy showed promising therapeutic results for metastatic colorectal cancer. In our preclinical and previous clinical studies, cytokine-induced killer (CIK) cells treatment for colorectal cancer showed favorable responses without toxicities. Here, we review current treatment options for colorectal cancer and summarize available clinical studies utilizing cell-based immunotherapy. Based on these studies, we recommend the use CIK cell therapy as a promising therapeutic strategy for patients with metastatic colorectal cancer.

Keyword

Cytokine-induced killer cells; Colorectal cancer; Cell-based immunotherapy

MeSH Terms

Cell- and Tissue-Based Therapy
Colorectal Neoplasms*
Cytokine-Induced Killer Cells*
Dendritic Cells
Drug Therapy, Combination
Humans
Immunotherapy*
Incidence
Lymph Nodes
Mortality
Prognosis
Quality of Life
Survival Rate
Vaccines
Vaccines